[go: up one dir, main page]

AU2003285503A1 - Screening method - Google Patents

Screening method

Info

Publication number
AU2003285503A1
AU2003285503A1 AU2003285503A AU2003285503A AU2003285503A1 AU 2003285503 A1 AU2003285503 A1 AU 2003285503A1 AU 2003285503 A AU2003285503 A AU 2003285503A AU 2003285503 A AU2003285503 A AU 2003285503A AU 2003285503 A1 AU2003285503 A1 AU 2003285503A1
Authority
AU
Australia
Prior art keywords
screening method
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003285503A
Inventor
John Raymond Bantick
Ian David Cook
David Keith Donald
Raymond Hutchinson
Andrew Paul Jackson
Clive Geoffrey Jackson
Clare Margaret Murray
Michael Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003285503A1 publication Critical patent/AU2003285503A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003285503A 2003-11-21 2003-11-21 Screening method Abandoned AU2003285503A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2003/005072 WO2005054852A1 (en) 2003-11-21 2003-11-21 Screening method

Publications (1)

Publication Number Publication Date
AU2003285503A1 true AU2003285503A1 (en) 2005-06-24

Family

ID=34639860

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003285503A Abandoned AU2003285503A1 (en) 2003-11-21 2003-11-21 Screening method

Country Status (3)

Country Link
EP (1) EP1697744A1 (en)
AU (1) AU2003285503A1 (en)
WO (1) WO2005054852A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005098444A2 (en) * 2003-07-03 2005-10-20 Xenoport, Inc. Monocarboxylate transporters expressed in cancer cells
EP1892530A1 (en) 2006-08-25 2008-02-27 Boehringer Ingelheim Pharma GmbH & Co. KG Method for determining transport activity of a transport protein
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CN107635404B (en) 2015-06-12 2021-09-28 威特瑞有限公司 MCT4 inhibitors for the treatment of disease
JP7123929B2 (en) 2016-12-12 2022-08-23 ベットーレ リミテッド ライアビリティー カンパニー Heterocyclic inhibitors of MCT4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504452A (en) * 1997-12-05 2002-05-31 Astrazeneca Uk Ltd [3,4-d]Pyridazinones, process for their preparation and pharmaceutical compositions containing them
WO2002022678A2 (en) * 2000-09-15 2002-03-21 Pe Corporation (Ny) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US20030166522A1 (en) * 2000-12-12 2003-09-04 Ketchum Karen A. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Also Published As

Publication number Publication date
WO2005054852A1 (en) 2005-06-16
EP1697744A1 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
GB0309397D0 (en) Screening methods
AU2003258070A1 (en) Electrodionization method
AU2003277663A1 (en) Screening method
AU2002249467A1 (en) Screening method
AU2003902613A0 (en) Self-surveying method
GB0304993D0 (en) Novel screening method
AU2003242340A1 (en) Novel screening method
AU2003901196A0 (en) Analysis method
AU2003285503A1 (en) Screening method
AU2003227268A1 (en) Novel screening method
AU2002952966A0 (en) Screening apparatus
AU2003242342A1 (en) Novel screening method
AU2003217008A1 (en) Screening method
AU2003278535A1 (en) Histoscreen method
AU2002354247A1 (en) Screening method
AU2003283943A1 (en) Method
AU2003248955A1 (en) Screening method
AU2003235310A1 (en) Novel screening method
AU2003257058A1 (en) Method for making alkyhalosilanes
AU2003210099A1 (en) New method
AU2003303311A1 (en) Methods for selecting and screening for trasformants
AU2003280725A1 (en) Screening method
AUPS286102A0 (en) Screening method
AU2003235120A1 (en) Screening method
AU2002952433A0 (en) Screening method

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase